IRIS
TOSCANI, Denise
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.662
EU - Europa 1.379
AS - Asia 933
SA - Sud America 31
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 6
Totale 4.038
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.636
CN - Cina 546
SE - Svezia 332
IE - Irlanda 309
IT - Italia 263
SG - Singapore 249
FI - Finlandia 149
DE - Germania 113
TR - Turchia 100
AT - Austria 50
FR - Francia 47
BR - Brasile 28
IN - India 26
BE - Belgio 24
CA - Canada 23
CI - Costa d'Avorio 21
CZ - Repubblica Ceca 19
RO - Romania 18
GB - Regno Unito 16
NL - Olanda 10
UA - Ucraina 8
EU - Europa 6
ES - Italia 5
LT - Lituania 5
BG - Bulgaria 3
DK - Danimarca 2
IL - Israele 2
IR - Iran 2
RU - Federazione Russa 2
SC - Seychelles 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
CM - Camerun 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
EG - Egitto 1
JP - Giappone 1
MD - Moldavia 1
MX - Messico 1
NG - Nigeria 1
OM - Oman 1
PH - Filippine 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 4.038
Salva come PNG Salva come JPEG
Città #
Chandler 310
Dublin 308
Santa Clara 200
Singapore 177
Ashburn 130
Beijing 126
Parma 116
Ann Arbor 108
Izmir 90
Shanghai 86
Boardman 78
Dearborn 74
Nanjing 64
New York 57
Princeton 56
Vienna 49
Shenyang 38
Marseille 34
Helsinki 27
Wilmington 26
Jacksonville 25
Brussels 24
Kunming 24
Munich 24
Hebei 23
Abidjan 21
Nanchang 20
Düsseldorf 18
Jinan 17
San Mateo 17
Toronto 17
Brno 16
Jiaxing 16
Los Angeles 15
Bremen 14
Hefei 14
Milan 14
Seattle 14
Norwalk 13
Tianjin 13
Kocaeli 10
Redmond 10
Woodbridge 10
Focsani 9
Bologna 7
Changsha 7
Dallas 7
Guangzhou 7
Rome 7
Des Moines 6
London 6
Ottawa 6
Pune 6
Zhengzhou 6
Ahmedabad 5
Chengdu 5
Palermo 5
Philadelphia 5
Torino 5
Borås 4
Frankfurt am Main 4
Fremont 4
Hangzhou 4
Houston 4
Madrid 4
Rockville 4
Savignano sul Rubicone 4
Taizhou 4
Washington 4
Cesena 3
Columbia 3
Fairfield 3
Lanzhou 3
Modena 3
Reggio Emilia 3
Rho 3
St Louis 3
Taiyuan 3
Wuhan 3
Amsterdam 2
Arcevia 2
Basingstoke 2
Belo Horizonte 2
Catania 2
Chicago 2
Chongqing 2
Cornaredo 2
Deiva Marina 2
Florence 2
Fuzhou 2
Harbin 2
L’Aquila 2
Medesano 2
Mestre 2
Nerviano 2
Ningbo 2
Osasco 2
Paris 2
Piacenza 2
Pilastro 2
Totale 2.754
Salva come PNG Salva come JPEG
Nome #
The Proteasome and Myeloma-Associated Bone Disease 113
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 111
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 105
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 101
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 93
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 92
Novel targets for the treatment of relapsing multiple myeloma 91
The osteoblastic niche in the context of multiple myeloma 90
Possible targets to treat myeloma-related osteoclastogenesis 88
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 87
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 87
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 84
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 84
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 84
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 83
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 83
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 82
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 81
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 79
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 79
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 78
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 77
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 75
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 75
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 75
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 74
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 73
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 73
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 72
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 72
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 70
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 70
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis 69
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 69
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 67
Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells 66
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 66
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 65
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 65
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 60
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis 56
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 55
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 54
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 53
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 52
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 52
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 51
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 50
The impact of CD56 expression in smoldering myeloma patients on early progression 49
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 47
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 43
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 43
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 42
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 42
The role of proteasome inhibitors in multiple myeloma bone disease and bone metastasis: Effects on osteoblasts and osteocytes 40
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 39
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 38
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 34
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 33
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 31
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease 29
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 26
Totale 4.167
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.221
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.221
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020260 0 0 0 0 0 64 44 7 43 68 15 19
2020/2021239 17 4 12 7 44 9 14 14 56 25 12 25
2021/2022284 6 5 9 27 9 6 41 32 13 16 23 97
2022/20231.282 144 139 92 99 101 140 41 80 372 30 31 13
2023/2024556 26 37 12 14 36 185 51 22 14 35 27 97
2024/2025699 34 75 89 154 176 171 0 0 0 0 0 0
Totale 4.167